Qing-Lin Peng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3003782/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Research and Therapy, 2017, 19, 259.	3.5	134
2	Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. Journal of Rheumatology, 2017, 44, 1051-1057.	2.0	123
3	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
4	Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyostis: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e94128.	2.5	96
5	Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. PLoS ONE, 2015, 10, e0141616.	2.5	66
6	Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Scientific Reports, 2017, 7, 188.	3.3	65
7	The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clinical Rheumatology, 2015, 34, 2097-2103.	2.2	47
8	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clinical Rheumatology, 2019, 38, 2171-2179.	2.2	41
9	Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clinical Rheumatology, 2019, 38, 1655-1663.	2.2	32
10	Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue. Journal of Rheumatology, 2015, 42, 979-987.	2.0	31
11	Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. Modern Rheumatology, 2017, 27, 122-129.	1.8	30
12	Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Scientific Reports, 2016, 6, 27479.	3.3	29
13	A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. Clinical and Experimental Immunology, 2020, 199, 314-325.	2.6	27
14	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. Journal of Rheumatology, 2018, 45, 835-840.	2.0	23
15	Discovery of new biomarkers of idiopathic inflammatory myopathy. Clinica Chimica Acta, 2015, 444, 117-125.	1.1	22
16	Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis. Scientific Reports, 2016, 6, 32818.	3.3	22
17	HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. PLoS ONE, 2016, 11, e0161436.	2.5	21
18	Differential Clinical Associations of Anti–Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2018, 70, 1288-1297.	5.6	20

QING-LIN PENG

#	Article	IF	CITATIONS
19	The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2016, 35, 2715-2721.	2.2	19
20	The RIC-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. Arthritis Research and Therapy, 2019, 21, 131.	3.5	17
21	The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study. Frontiers in Pharmacology, 2021, 12, 635654.	3.5	16
22	Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. Seminars in Arthritis and Rheumatism, 2021, 51, 741-748.	3.4	16
23	Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. Journal of Immunology Research, 2019, 2019, 1-12.	2.2	14
24	Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. Arthritis Research and Therapy, 2021, 23, 15.	3.5	14
25	B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomarkers in Medicine, 2014, 8, 395-403.	1.4	13
26	Plasma exosomal RNAs have potential as both clinical biomarkers and therapeutic targets of dermatomyositis. Rheumatology, 2022, 61, 2672-2681.	1.9	12
27	Necroptosis contributes to myofiber death in idiopathic inflammatory myopathies. Arthritis and Rheumatology, 2022, , .	5.6	11
28	The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. Clinical Rheumatology, 2018, 37, 1573-1580.	2.2	10
29	Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217096.	0.9	10
30	Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 628128.	3.7	10
31	Aberrant expansion of circulating CD4 ⁺ CXCR5 ⁺ CCR7 ^{lo} PD1 ^{hi} Tfh precursor cells in idiopathic inflammatory myopathy. International Journal of Rheumatic Diseases, 2020, 23, 397-405.	1.9	8
32	Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis. Mediators of Inflammation, 2020, 2020, 1-11.	3.0	8
33	Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology, 2022, 62, 397-406.	1.9	8
34	Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. International Journal of Rheumatic Diseases, 2017, 20, 252-260.	1.9	6
35	Targeted capture sequencing identifies novel genetic variations in Chinese patients with idiopathic inflammatory myopathies. International Journal of Rheumatic Diseases, 2018, 21, 1619-1626.	1.9	6
36	Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort. BMC Musculoskeletal Disorders, 2022, 23, 425.	1.9	6

QING-LIN PENG

#	Article	IF	CITATIONS
37	Serum levels of anti-transcriptional intermediary factor 1-Î ³ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. Seminars in Arthritis and Rheumatism, 2022, 55, 152011.	3.4	4
38	Resistin Expression Is Associated With Interstitial Lung Disease in Dermatomyositis. Frontiers in Medicine, 2022, 9, 903887.	2.6	2
39	miR-18a-3p and Its Target Protein HuR May Regulate Myogenic Differentiation in Immune-Mediated Necrotizing Myopathy. Frontiers in Immunology, 2021, 12, 780237.	4.8	1
40	ldentification of a novel autoantibody against heat shock factor 1 in idiopathic inflammatory myopathy. Clinical and Experimental Rheumatology, 2020, 38, 1191-1200.	0.8	1
41	The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients. Frontiers in Medicine, 2022, 9, 771784.	2.6	1
42	FRI0524â€Elevated HMGB1 and Decreased Micrornas Expression in Polymyositis: Potential Contributions to Muscle Inflammation and Degeneration. Annals of the Rheumatic Diseases, 2014, 73, 577.1-577.	0.9	0
43	FRI0308â€HIGH LEVEL OF SERUM NEOPTERIN IS ASSOCIATED WITH RAPIDLY PROGRESSIVE INTERSTITIAL LUN DISEASE AND REDUCED SURVIVAL IN DERMATOMYOSITIS. , 2019, , .	G	0
44	OP0181â€MOLECULAR CHARACTERIZATION AND STRATIFICATION OF IDIOPATHIC INFLAMMATORY MYOPATH ON THE BASIS OF SKELETAL MUSCLE TRANSCRIPTOME STUDY. , 2019, , .	HES:	0